916971-29-4

Basic information

• Product Name: 4-(2-Bromo-phenoxy)-piperidine
• Synonyms: 4-(2-Bromo-phenoxy)-piperidine
• CAS NO: 916971-29-4
• Molecular Formula: C11H14BrNO
• Molecular Weight: 256.13896
• Mol File: 916971-29-4.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(2-Bromo-phenoxy)-piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-Bromo-phenoxy)-piperidine(916971-29-4)
• EPA Substance Registry System: 4-(2-Bromo-phenoxy)-piperidine(916971-29-4)

Safety Data

• Hazardous Substances Data: 916971-29-4(Hazardous Substances Data)

Usage

Chemical Structure

It consists of a piperidine ring bonded to a phenoxy group, with a bromine atom at the 2-position.

Usage

Commonly utilized as a building block in organic synthesis.

Applications

Acts as a precursor in the preparation of various pharmaceuticals and fine chemicals.

Safety Precautions

Handling requires caution due to potential health hazards.

Ventilation

It should be used in a well-ventilated area.

Protective Equipment

Appropriate protective gear should be worn during handling.

Hazardous Nature

It may pose risks to health and safety.

Handle with Care

Due to its hazardous nature, careful handling is necessary.

Upstream product

• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 95-56-7 2-hydroxybromobenzene 
• 444605-55-4 1,1-dimethylethyl 4-[(2-bromophenyl)oxy]-1-piperidinecarboxylate 

Relevant articles and documents

Identification of a new series of benzothiazinone derivatives with excellent antitubercular activity and improved pharmacokinetic profiles

Nitrobenzothiazinone (BTZ) is a promising scaffold with potent activity against M. tuberculosis by inhibiting decaprenylphosphoryl-beta-d-ribose 2′-oxidase (DprE1). But unfavorable durability poses a challenge to further development of this class of agents. Herein, a series of BTZs bearing a variety of different substituents at the C-2 position were designed and synthesized. Compounds were screened for their antimycobacterial activity against Mycobacterium tuberculosis H37Ra and were profiled for metabolic stability, plasma protein-binding capacity and pharmacokinetics in vivo. In general, these new BTZs containing N-piperazine, N-piperidine or N-piperidone moiety have excellent antitubercular activity and low cytotoxicity. Several of the compounds showed improved microsomal stability and lower plasma protein-binding, opening a new direction for further lead optimization. And we obtained compound 3o, which maintained good anti-tuberculosis activity (MIC = 8 nM) and presented better in vitro ADME/T and in vivo pharmacokinetic profiles than reported BTZ compound PBTZ169, which may serve as a candidate for the treatment of tuberculosis.